E

Evolution Research Group | Richmond Behavioral Associates

Research site
(Unclaimed)
Location
260 Christopher Lane, staten island, New York, United States of America

Site insights

Top conditions

Top treatments

Aripiprazole
SPD489
Lurasidone
Troriluzole
Gantenerumab
Rapastinel
BI 409306
Balovaptan
SPD503
Iclepertin

Parent organization

This site is a part of Evolution Research Group

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

28 of 107 total trials

A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy (REGAiN-1B)

To evaluate the durability of efficacy and long-term safety of intramuscular (IM) administration of Engensis or Placebo that was administered in the...

Enrolling
Diabetic Peripheral Neuropathy
Biological: Engensis
Other: Placebo

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disea...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: AL002

Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in ba...

Enrolling
Treatment Resistant Depression
Device: Vagus Nerve Stimulation (VNS)

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer´s Disease
Drug: Placebo (semaglutide)
Drug: Semaglutide

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer's Disease
Drug: Placebo (semaglutide)
Drug: Semagludtide

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequ...

Enrolling
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules
Drug: Placebo

This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP385 in the treatm...

Active, not recruiting
Essential Tremor
Drug: JZP385
Other: Placebo

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of t...

Enrolling
Schizophrenia
Drug: Iclepertin

This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. Th...

Active, not recruiting
Early Alzheimer's Disease
Drug: Experimental: ALZ-801
Drug: Placebo Comparator: Placebo

This is a Phase III, open label extension study evaluating the continued safety and efficacy of CM-AT in pediatric patients with autism with all leve...

Active, not recruiting
Autism
Drug: CM-AT

This is a single-arm, open-label Phase 2 study to assess the safety, tolerability, pharmacokinetics (PK), and activity of ANC-501 oral capsules as ad...

Active, not recruiting
Major Depressive Disorder
Drug: ANC-501

This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Example...

Active, not recruiting
Schizophrenia
Drug: Iclepertin
Drug: Placebo

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compul...

Enrolling
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Enrolling
Treatment Resistant Depression
Drug: Psilocybin

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Enrolling
Generalized Anxiety Disorder
Drug: Placebo
Drug: ENX-102

This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2...

Enrolling
Agitation in Patients With Dementia of the Alzheimer's Type
Drug: AVP-786

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatmen...

Enrolling
Agitation
Alzheimer's Type Dementia
Drug: Masupirdine 100 mg
Drug: Masupirdine 50 mg

Trial sponsors

Otsuka logo
Shire logo
Roche logo
Sumitomo Pharma logo
Boehringer Ingelheim logo
Allergan logo
Biohaven logo
J
Jazz Pharmaceuticals logo
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems